Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 699% % 323%
Debt-to-equity 14% % -82%
Return On Equity -23% % 88%
Return On Assets -20% % 81%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 83,992,407 shares 23%
Common Stock, Shares, Outstanding 74,696,629 shares 10%
Entity Public Float $251,900,000 USD 265%
Common Stock, Value, Issued $7,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 78,964,842 shares 29%
Weighted Average Number of Shares Outstanding, Diluted 79,742,685 shares 31%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $33,719,000 USD 74%
General and Administrative Expense $9,252,000 USD 13%
Operating Income (Loss) $42,971,000 USD -56%
Nonoperating Income (Expense) $415,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $15,283,000 USD 75%
Earnings Per Share, Basic -0.19 USD/shares 81%
Earnings Per Share, Diluted -0.53 USD/shares 48%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,576,000 USD -48%
Cash, Cash Equivalents, and Short-term Investments $56,800,000 USD 9.2%
Accounts Receivable, after Allowance for Credit Loss, Current $37,000 USD -51%
Other Assets, Current $318,000 USD -42%
Assets, Current $58,214,000 USD 7%
Property, Plant and Equipment, Net $220,000 USD 46%
Operating Lease, Right-of-Use Asset $839,000 USD -29%
Other Assets, Noncurrent $855,000 USD 35%
Assets $71,119,000 USD 3.2%
Accounts Payable, Current $2,491,000 USD -3.5%
Employee-related Liabilities, Current $641,000 USD -22%
Accrued Liabilities, Current $6,486,000 USD 74%
Liabilities, Current $9,380,000 USD -74%
Operating Lease, Liability, Noncurrent $534,000 USD -43%
Liabilities $9,914,000 USD -73%
Accumulated Other Comprehensive Income (Loss), Net of Tax $896,000 USD 30%
Retained Earnings (Accumulated Deficit) $412,293,000 USD -3.8%
Stockholders' Equity Attributable to Parent $61,205,000 USD 88%
Liabilities and Equity $71,119,000 USD 3.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,263,000 USD -60%
Net Cash Provided by (Used in) Financing Activities $279,000 USD
Net Cash Provided by (Used in) Investing Activities $4,243,000 USD
Common Stock, Shares Authorized 290,000,000 shares 0%
Common Stock, Shares, Issued 74,696,629 shares 10%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,741,000 USD 28%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,576,000 USD -48%
Deferred Tax Assets, Valuation Allowance $102,099,000 USD 13%
Deferred Tax Assets, Gross $102,348,000 USD 13%
Operating Lease, Liability $354,000 USD
Payments to Acquire Property, Plant, and Equipment $36,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $14,891,000 USD 76%
Lessee, Operating Lease, Liability, to be Paid $358,000 USD
Property, Plant and Equipment, Gross $2,869,000 USD -40%
Operating Lease, Liability, Current $403,000 USD 118%
Operating Lease, Weighted Average Discount Rate, Percent 0.117 pure 46%
Deferred Tax Assets, Operating Loss Carryforwards $75,433,000 USD 18%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $13,503,000 USD 2.8%
Operating Lease, Payments $157,000 USD -67%
Additional Paid in Capital $474,387,000 USD 10%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $22,000 USD -4.3%
Share-based Payment Arrangement, Expense $5,330,000 USD 77%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%